Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital
Brief: Alzamend Neuro Inc - Enters ATM Sales Agreement To Sell Up To $3.0 Million In Common Stock - SEC Filing
U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet
U.S. STOCKS ON THE MOVE-Constellation Energy, Williams-Sonoma
U.S. STOCKS ON THE MOVE-Lowe's, TJX Companies, Target
Brief: Alzamend Neuro Announces Completion Of Clinical Portion Of Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study Conducted At Massachusetts General Hospital
Alzamend rises after completing mid-stage brain lithium study
U.S. RESEARCH ROUNDUP- Apogee Therapeutics, Intel, Northern Trust
Brief: Alzamend Neuro Announces Dosing Of First Patient In Phase II Clinical Trial Of Al001 “Lithium In Brain” Study
Brief: Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study
Brief: Alzamend Neuro plans mid-stage study of its therapy for PTSD in fourth-quarter 2025
Brief: Alzamend Neuro Announces Initiation Date Of Phase II Clinical Trial Of AL001 For Treatment Of Bipolar Disorder To Take Place At Massachusetts General Hospital
Brief: Alzamend Neuro Announces Completion Of A Novel Head Coil By Tesla For Measuring Brain Structure Lithium Levels In Five Upcoming Phase Ii Clinical Trials At Massachusetts General Hospital
Brief: Alzamend Neuro Announces Full Data Set From Its Nonclinical Study